Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation Among Patients at Risk of Aspiration

JAMA. 2023 May 2;329(17):1517-1518. doi: 10.1001/jama.2023.3491.

Authors

Hugo Carvalho¹, Alain Kalmar², Sarah Saxena²

Affiliations

¹ Department of Anesthesiology and Perioperative Medicine, Universitair Ziekenhuis Brussels, Brussels, Belgium.
² Department of Anesthesia and Resuscitation, AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium.

PMID: 37129660
DOI: 10.1001/jama.2023.3491

No abstract available

Publication types

Comment

MeSH terms

Analgesics, Opioid* / administration & dosage
Analgesics, Opioid* / pharmacology
Analgesics, Opioid* / therapeutic use
Anesthetics, Intravenous
Blood Pressure / drug effects
Heart Rate / drug effects
Humans
Intubation, Intratracheal / adverse effects
Intubation, Intratracheal / methods
Neuromuscular Blocking Agents* / administration & dosage
Neuromuscular Blocking Agents* / pharmacology
Neuromuscular Blocking Agents* / therapeutic use
Rapid Sequence Induction and Intubation* / adverse effects
Rapid Sequence Induction and Intubation* / methods
Remifentanil* / administration & dosage
Remifentanil* / pharmacology
Remifentanil* / therapeutic use
Respiratory Aspiration* / etiology
Respiratory Aspiration* / prevention & control
Risk

Substances

Anesthetics, Intravenous
Neuromuscular Blocking Agents
Remifentanil
Analgesics, Opioid